Citizens JMP raised the firm’s price target on Protagonist Therapeutics (PTGX) to $69 from $67 and keeps an Outperform rating on the shares following the Q2 report. The company remains on track to submit its application for rusfertide in polycythemia vera next quarter, with two new candidates nearing clinical testing, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics: Promising Future with Strong Pipeline and Financial Stability
- Protagonist Therapeutics Reports Q2 2025 Results and Pipeline Progress
- Protagonist Therapeutics: Promising Developments in Rusfertide and Icotrokinra Drive Buy Rating
- Protagonist Therapeutics files automatic mixed securities shelf
- Protagonist Therapeutics reports Q2 EPS (55c), consensus (52c)